ClinicalTrials.gg
CompletedNCT02493855Updated Oct 31, 2017Results posted

Ombitasvir/ABT-450/Ritonavir and Dasabuvir Therapy With Low Dose Ribavirin (RBV), Full Dose RBV or RBV Add-On in Treatment Naive Genotype 1a Hepatitis C Virus Infected Adults

A Phase 2 interventional study of Ombitasvir/ABT-450/Ritonavir and Dasabuvir in Chronic Hepatitis C, Hepatitis C (HCV) and Hepatitis C Genotype 1a, sponsored by AbbVie. Completed. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2017-10-31.

Sponsored by AbbVie · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 19 studies testing ombitasvir in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. ombitasvir · Hepatitis C, Chronic.

Enrollment
13th of 19
46 · median 148
Started
2015
with 6 others
Phase 2
7 of 19
none open now
Registered
15th of 19
by date
Lead sponsor
8 of 19
AbbVie

Among the 19 studies testing ombitasvir in Hepatitis C, Chronic, this one is the 13th largest by enrollment, is one of 7 that started in 2015, is one of 7 in phase 2, and was the 15th registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 19 studies testing ombitasvir in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →

About ombitasvir

ombitasvir: first FDA approval 2014 (VIEKIRA PAK (COPACKAGED)), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies testing ombitasvir in Hepatitis C, Chronic as a file.
02

Study summary

To evaluate the effect of ribavirin on second phase plasma hepatitis C virus (HCV) ribonucleic acid (RNA) decline in participants who receive ombitasvir/ABT-450/ritonavir and dasabuvir with full dose ribavirin, low dose ribavirin or without ribavirin for 2 weeks in treatment-naive HCV genotype (GT) 1a-infected adults.

03

Conditions studied

  • Chronic Hepatitis C
  • Hepatitis C (HCV)
  • Hepatitis C Genotype 1a

Keywords

  • Treatment naive
  • HCV
  • Interferon free
  • Hepatitis C Genotype 1a
  • Chronic Hepatitis C
  • Hepatitis C
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Screening laboratory result indicating genotype 1 (GT1) a infection.
  2. Chronic HCV infection.
  3. Subjects must be non-cirrhotic.
  4. Subjects must be able to understand and adhere to the study visit schedule and all protocol requirements as well as voluntarily sign and date an institutional review board (IRB) approved .

Exclusion criteria

Exclusion Criteria:

  1. Women who are pregnant or breastfeeding.
  2. Positive test result for surface antigen (HBsAg) or anti- antibody (HIV Ab) positive immunoassay.
  3. abnormalities or co-morbidities, other than infection, that make the subject unsuitable for this study or treatment.
  4. Current enrollment in another interventional clinical study. Previous use of any HCV treatments including pegylated interferon (pegIFN), ribavirin, or any direct acting antiviral agent, either or approved, for HCV including protease inhibitors, nucleoside or non-nucleoside polymerase inhibitors, or nonstructural viral protein 5A (NS5A) inhibitors.
  5. History or solid organ transplant.
  6. Screening laboratory analysis that shows abnormal results.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    Arm A: Ribavirin Full Dose for Last 10 Weeks

    Participants received ombitasvir/ABT-450/ritonavir 25 mg/150 mg/100 mg once daily (QD) + dasabuvir 250 mg twice daily (BID) for 12 weeks and weight-based ribavirin (1000 mg or 1200 mg split BID) for the last 10 weeks.

    Drug: Ombitasvir/ABT-450/Ritonavir · Drug: Dasabuvir · Drug: Ribavirin (RBV)

  • Experimental
    Arm B: Ribavirin Full Dose for 12 Weeks

    Participants received ombitasvir/ABT-450/ritonavir 25 mg/150 mg/100 mg once daily (QD) + dasabuvir 250 mg twice daily (BID) and weight-based ribavirin (1000 mg or 1200 mg split BID) for 12 weeks.

    Drug: Ombitasvir/ABT-450/Ritonavir · Drug: Dasabuvir · Drug: Ribavirin (RBV)

  • Experimental
    Arm C: Ribavirin Low-dose for 12 Weeks

    Participants received ombitasvir/ABT-450/ritonavir 25 mg/150 mg/100 mg once daily (QD) + dasabuvir 250 mg twice daily (BID) and 600 mg ribavirin once daily for 12 weeks.

    Drug: Ombitasvir/ABT-450/Ritonavir · Drug: Dasabuvir · Drug: Ribavirin (RBV)

Interventions

06

What researchers measure

Primary outcomes

  1. Slope of the Second Phase Decline in Plasma HCV Ribonucleic Acid (RNA) Levels During Treatment

    HCV viral kinetics in plasma during therapy were modeled through non-linear mixed effect models, including a rapid first phase of initial decline and a slower second phase decline. The slope of the second phase decline was estimated for each treatment arm.

    Time frame: From Week 0 to Week 2

07

Results

Posted May 15, 2017

Participant flow

This study was conducted at one clinic in France and one clinic in the United States. Participants were treatment-naïve adults with hepatitis C virus (HCV) genotype (GT)1a infection without cirrhosis.

Participant flow — Overall Study
MilestoneArm A: Ribavirin Full Dose for Last 10 WeeksArm B: Ribavirin Full Dose for 12 WeeksArm C: Ribavirin Low-dose for 12 Weeks
Started21196
Completed19186
Not completed210
Withdrew: Non-compliance100
Withdrew: Adverse event010
Withdrew: Withdrawal by subject100

Outcome measures

PrimarySlope of the Second Phase Decline in Plasma HCV Ribonucleic Acid (RNA) Levels During Treatment

HCV viral kinetics in plasma during therapy were modeled through non-linear mixed effect models, including a rapid first phase of initial decline and a slower second phase decline. The slope of the second phase decline was estimated for each treatment arm.

Time frame:
From Week 0 to Week 2
Reported as:
Median · 1/day
Slope of the Second Phase Decline in Plasma HCV Ribonucleic Acid (RNA) Levels During Treatment
1/dayArm A: Ribavirin Full Dose for Last 10 WeeksArm B: Ribavirin Full Dose for 12 WeeksArm C: Ribavirin Low-dose for 12 Weeks
Slope of the Second Phase Decline in Plasma HCV Ribonucleic Acid (RNA) Levels During Treatment0.0036 (0.0006 to 0.0128)0.0046 (-0.0003 to 0.0155)0.0051 (0.0031 to 0.0076)
Statistical analysis
  • Arm A: Ribavirin Full Dose for Last 10 Weeks vs Arm B: Ribavirin Full Dose for 12 Weeks · Wilcoxon Rank Sum Test · p = 0.311
  • Arm B: Ribavirin Full Dose for 12 Weeks vs Arm C: Ribavirin Low-dose for 12 Weeks · Wilcoxon Rank Sum Test · p = 0.561

Adverse events

Collected over From first dose of study drug until 30 days after last dose; up to 16 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A: Ribavirin Full Dose for Last 10 Weeks—1/21 (4.8%)17/21 (81%)
Arm B: Ribavirin Full Dose for 12 Weeks—0/19 (0%)16/19 (84.2%)
Arm C: Ribavirin Low-dose for 12 Weeks—0/6 (0%)6/6 (100%)
Most frequent serious events
Most frequent serious events
EventArm A: Ribavirin Full Dose for Last 10 WeeksArm B: Ribavirin Full Dose for 12 WeeksArm C: Ribavirin Low-dose for 12 Weeks
DEPRESSIONPsychiatric disorders1/210/190/6
DRUG DEPENDENCEPsychiatric disorders1/210/190/6
Most frequent other events
Showing 10 of 81
Most frequent other events
EventArm A: Ribavirin Full Dose for Last 10 WeeksArm B: Ribavirin Full Dose for 12 WeeksArm C: Ribavirin Low-dose for 12 Weeks
PROCEDURAL PAINInjury, poisoning and procedural complications7/215/195/6
DYSPEPSIAGastrointestinal disorders0/212/193/6
FATIGUEGeneral disorders5/217/192/6
ANAEMIABlood and lymphatic system disorders4/214/192/6
DRY MOUTHGastrointestinal disorders1/211/192/6
NAUSEAGastrointestinal disorders3/213/192/6
HYPERBILIRUBINAEMIAHepatobiliary disorders2/210/192/6
BACK PAINMusculoskeletal and connective tissue disorders2/211/192/6
RASHSkin and subcutaneous tissue disorders0/211/192/6
PRURITUSSkin and subcutaneous tissue disorders3/216/191/6

Baseline characteristics

Age, Continuous
Age, Continuous(years)Arm A: Ribavirin Full Dose for Last 10 WeeksArm B: Ribavirin Full Dose for 12 WeeksArm C: Ribavirin Low-dose for 12 WeeksTotal
Mean44.9 ± 11.9646.0 ± 12.7836.7 ± 15.7944.3 ± 12.88
Age, Customized
Age, Customized(Participants)Arm A: Ribavirin Full Dose for Last 10 WeeksArm B: Ribavirin Full Dose for 12 WeeksArm C: Ribavirin Low-dose for 12 WeeksTotal
< 55 years1714536
≥ 55 - 65 years45110
≥ 65 years0000
Sex: Female, Male
Sex: Female, Male(Participants)Arm A: Ribavirin Full Dose for Last 10 WeeksArm B: Ribavirin Full Dose for 12 WeeksArm C: Ribavirin Low-dose for 12 WeeksTotal
Female1112427
Male107219
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Arm A: Ribavirin Full Dose for Last 10 WeeksArm B: Ribavirin Full Dose for 12 WeeksArm C: Ribavirin Low-dose for 12 WeeksTotal
White1614434
Black of African American4318
Asian0000
American Indian or Alaskan Native0000
Native Hawaiian or Other Pacific Islander0000
Mutli Race1214
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2015 to primary completion in Apr 2016, 10 months.

Results were first posted in May 2017, 1 year 1 month after primary completion.

Of 28 industry-sponsored phase 2 interventional studies under Hepatitis C, Chronic, half reached primary completion within 16 months of starting (the median); a quarter within 10 and three quarters within 28. This study's 10 months is below that.

Counting every sponsor, half of 35 studies reached it within 17 months; a quarter within 11 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2015
First posted
Jul 10, 2015
StartActual
Jun 2015
Primary completionActual
Apr 2016
CompletionActual
Dec 2016
Results first posted
May 15, 2017
Last update
Oct 31, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 31, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02493855
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jul 10, 2015
Start date
Jun 2015
Primary completion
Apr 2016
Completion
Dec 2016
Results posted
May 15, 2017
Last update
Oct 31, 2017

Study contacts

Emily Dumas, PhD
study director · AbbVie

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ombitasvir · Paritaprevir · Ritonavir · Dasabuvir · Ribavirin

Start the discussion